Transgene has recently broadened its myvac® platform to include Non-Small Cell Lung Cancer (NSCLC) with the introduction of TG4070, a personalized neoantigen therapeutic vaccine. This development marks a significant milestone for the company as it aims to cater to a broader range of cancer patients. The myvac® platform allows for the creation of individualized vaccines tailored to specific neoantigens present in a patient's tumor. The expansion into NSCLC is particularly promising given its prevalence, as it accounts for approximately 85% of all lung cancer cases. TG4070 shows great potential in delivering personalized treatment options for NSCLC patients, showcasing Transgene's commitment to advancing innovative therapies in the field of oncology.